Recent insights into gastric cancer with peritoneal metastasis (gcpm) reveal dismal outcomes, underscoring the need for improved management strategies. A growing body of clinical trials investigates the efficacy of cytoreductive surgery (crs) combined with hyperthermic intraperitoneal chemotherapy (hipec), recognized in new national guidelines. Enhanced understanding of gcpm’s mechanisms and novel therapeutic targets could lead to breakthroughs in overcoming treatment resistance. This review synthesizes advancements and current guidelines, addressing the ongoing challenges in gcpm management.
Review by Lewis KA, Diggs LP and Badgwell BD in Ann Surg Oncol
© 2025. Society of Surgical Oncology.